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Abstract Criteria for the staging and grading of neuroen-
docrine tumors (NETs) of midgut and hindgut origin were
established at the second Consensus Conference in Frascati
(Rome) organized by the European Neuroendocrine Tumor
Society (ENETS). The proposed tumor–node–metastasis
(TNM) classifications are based on the recently published
ENETS Guidelines for the Diagnosis and Treatment of
gastroenteropancreatic NETs and follow our previous
proposal for foregut tumors. The new TNM classifications
for NETs of the ileum, appendix, colon, and rectum, and the
grading system were designed, discussed, and consensually
approved by all conference participants. These proposals
need to be validated and are meant to help clinicians in the
stratification, treatment and follow-up of patients.
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Background
Based on recognized differences in morphology, function
and clinical behavior [1, 2, 21, 30], the current WHO
classification provides a prognosis-oriented definition of
gastroenteropancreatic neuroendocrine tumors (GEP-NETs)
[3, 5, 8, 12, 13, 34].
All GEP-NETs probably have a malignant potential, but
their biological behavior differs from tumor type to tumor
type [9, 10, 14–17, 22, 25, 26, 36]. Given their rarity [10,
14–17], correct diagnosis and appropriate treatment are
often difficult in nonexpert settings and even for appendi-
ceal “carcinoids,” probably the best known GEP-NETs with
the most benign behavior [31]. Recent data on ileal,
appendiceal, and rectal carcinoids, also indicated several
variables influencing survival and prognosis [6, 15, 29, 35].
Guidelines for the management of patients with GEP-
NETs were developed by the recently established European
Neuroendocrine Tumor Society (ENETS) [23, 37]. In two
separate meetings a consensus was sought on these guide-
lines. The papers deriving from the first conference dedicated
to foregut tumors, including a detailed tumor–node–
metastasis (TNM)/staging and grading proposals, have
been published meanwhile [4, 27]. The “Consensus
Conference on the ENETS Guidelines for the Diagnosis
and Treatment of Neuroendocrine Gastrointestinal Tumors,
Part 2: Midgut and Hindgut Tumors” was held in Frascati
(Rome, Italy) from November 1 to 4, 2006. In this paper, we
present the TNM staging and grading proposals for pure
NETs of the lower jejunum/ileum, appendix, and colon/rectum.
Materials and methods
Fifty-seven experts in the field of GEP-NETs from 18
different countries attended the consensus conference. The
attendees represented all medical branches involved in
managing patients with GEP-NETs. They formed four
working groups according to their specific clinical exper-
tise: (1) pathology and genetics (11 participants, all listed as
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coauthors), (2) surgery (8 participants), (3) imaging and
radiology (7 participants), (4) medicine and clinical
pathology (31 participants, including the coauthor B.W.).
Most of the participants also attended the first consensus
conference held in Frascati in November 2005.
The conference was divided sequentially into five sessions
devoted to specific topics on an anatomical basis (ileal well-
differentiated NETs; appendiceal well differentiated NETs;
colorectal well differentiated NETs; NETs metastatic to the
liver; poorly differentiated neuroendocrine carcinomas of
midgut and hindgut origin).
A working booklet with the ENETS guidelines text [23]
and specific queries had been prepared in advance by the
organizing committee. The work was organized as previously
detailed [4, 27]. This procedure was followed for all five
sessions. The TNM staging proposal was prepared by the
pathology and genetics working group and amended and
approved by the plenary session of the consensus conference.
The grading system was mainly discussed and defined by the
pathology and genetics working group.
Results and discussion
The consensus guidelines have been reported elsewhere.
The TNM staging proposal for NETs of midgut and hindgut
origin together with a grading system is intended to reflect,
like its forerunner for the NETs of the stomach, duodenum
and pancreas [27], the prognostic assessment by the
pathologist. The intestinal NETs were separated into lower
jejunum/ileum, appendix, and colon/rectum, but were not
distinguished according to specific functional activity, main
tumor cell type, or genetic background.
TNM staging proposal
The currently published TNM format was adopted as
working template (see Tables 1, 2, 3, 4, 5, and 6) [32].
Tumor There is no proposed definition for in situ endocrine
tumor of the jejunum, ileum, appendix, colon and rectum,
because no specific precursor lesion has been described in
the literature so far. For the lower jejunum and ileum, the
size limits indicated for T1 and T2 are those defined for
tumors of “benign behavior” and “uncertain behavior,”
respectively, according to the WHO site-specific clinico-
pathological correlations [5, 8, 34]. For the appendix and
colon and rectum tumors, lower size limits were defined for
T1 and T2 based on current data [6, 15, 29]. For colon and
rectum tumors, T1 was divided into T1A and T1B based on
current information on the biology of tumors below 1 cm in
size and between 1 and 2 cm [6].
Deeply invasive and large tumors are included in the T3
and T4 categories, taking into account site-specific features.
For any T definition, the maximum tumor size should be
reported and, in the case of multiple lesions, the largest one.
The use of T3 category subdivision (pT3a, b, c, and d)
according to distance below or higher than 5 mm from
muscularis propria as proposed for the adenocarcinoma
[33], could be of value. Its application could be imple-
mented once data on endocrine carcinomas will be
generated.
Lymph nodes N1 indicates the presence of any single or
multiple metastases in the regional lymph node group,
according to TNM rules. A minimum of 12 nodes should
be identified in a surgical specimen, assessed and, when
possible, named according to their location in relation to
tumor. Although regional lymph node metastases are a
negative prognostic factor in GEP-NETs [11], the signifi-
Table 1 Proposal for a TNM classification for endocrine tumors of
lower jejunum and ileum
TNM
T-primary tumor
TX Primary tumor cannot be assessed
T0 No evidence of primary tumor
T1 Tumor invades mucosa or submucosa and size ≤1 cm
T2 Tumor invades muscularis propria or size >1 cm
T3 Tumor invades subserosa
T4 Tumor invades peritoneum/other organs
For any T add (m) for multiple tumors
N regional lymph nodes
NX Regional lymph nodes cannot be assessed
N0 No regional lymph node metastasis
N1 Regional lymph node metastasis
M Distant metastasis
MX Distant metastasis cannot be assessed
M0 No distant metastases
M1a Distant metastasis
aM1 specific sites defined according to Sobin LH, Wittekind C [32].









Stage I T1 N0 M0
Stage IIA T2 N0 M0
Stage IIB T3 N0 M0
Stage IIIA T4 N0 M0
Stage IIIB Any T N1 M0
Stage IV Any T Any N M1
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cance of the number of metastatic nodes is not yet known.
Therefore, similar to the previous foregut TNM proposal,
the N1 status in stage IIIB in Tables 1, 2, 3, 4, 5, and 6 has
to be specified with regard to the number of lymph nodes
involved to allow validation.
Distant metastasis M1 indicates the presence of any single or
multiple metastases at any distant anatomical site (including
nonregional nodes). As extrahepatic bone metastases are a
negative prognostic factor [7, 21], it is recommended to
specify the anatomical site of the metastasis according to the
TNM classification rules (PUL, pulmonary; HEP, hepatic;
OSS, osseous; etc.) [32].
Staging Stage I encompasses the T1 NETs with limited
growth. Stage II identifies tumors that are larger in size or
more invasive, either T2 or T3, although always in the
absence of metastasis. At stage III, the increased malignancy
refers either to invasion into surrounding structures (Stage
IIIA) or to the presence of regional node metastases (Stage
IIIB). Stage IV always implies the presence of distant
metastases.
Grading proposal
Grading Studies on well-differentiated NETs of midgut and
hindgut origin have shown the usefulness of a grading
system (see Table 7) [6, 35, 36]. Well-differentiated
endocrine tumors with proliferative activity greater than
2%, but below that usually found in poorly differentiated
endocrine carcinomas, may have a prognosis intermediate
between the “2% NETs” and poorly differentiated carcino-








Stage I T1 N0 M0
Stage IIA T2 N0 M0
Stage IIB T3 N0 M0
Stage IIIA T4 N0 M0
Stage IIIB Any T N1 M0
Stage IV Any T Any N M1




TX Primary tumor cannot be assessed
T0 No evidence of primary tumor
T1 Tumor ≤1 cm invading submucosa and muscularis
propria
T2 Tumor ≤2 cm invading submucosa, muscularis propria
and/or minimally (up to 3 mm) invading subserosa/
mesoappendix
T3 Tumor >2 cm and/or extensive (more than 3 mm)
invasion of subserosa/mesoappendix
T4 Tumor invades peritoneum/other organs
N-regional lymph nodes
NX Regional lymph nodes cannot be assessed
N0 No regional lymph node metastasis
N1 Regional lymph node metastasis
M-distant metastasis
MX Distant metastasis cannot be assessed
M0 No distant metastases
M1a Distant metastasis
aM1 specific sites defined according to Sobin LH and Wittekind Ch
[32].




TX Primary tumor cannot be assessed
T0 No evidence of primary tumor
T1 Tumor invades mucosa or submucosa
T1a size <1 cm
T1b size 1–2 cm
T2 Tumor invades muscularis propria or size >2 cm
T3 Tumor invades subserosa/pericolic/perirectal fat
T4 Tumor directly invades other organs/structures and/or
perforates visceral peritoneum
For any T add (m) for multiple tumors
N-regional lymph nodes
NX Regional lymph node status cannot be assessed
N0 No regional lymph node metastasis
N1 Regional lymph node metastasis
M-distant metastases (subspecification as in small bowel)
MX Distant metastasis cannot be assessed
M0 No distant metastases
M1a Distant metastasis
aM1 specific sites defined according to Sobin LH and Wittekind Ch
[32].








Stage IA T1a N0 M0
Stage IB T1b N0 M0
Stage IIA T2 N0 M0
Stage IIB T3 N0 M0
Stage IIIA T4 N0 M0
Stage IIIB Any T N1 M0
Stage IV Any T Any N M1
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mas [18–20, 23, 24]. We decided to follow the same
grading system proposal as that devised for foregut tumors,
with the aim of distinguishing G2 from G1 and G3 GEP-
NETs. The three tumor categories are defined as follows:
G1, <2 mitoses per 2 mm2 (10 high-power fields, HPF, 40×
magnification) and/or Ki-67 index ≤2%; G2, 2–20 mitoses
per 2 mm2 and/or Ki-67 index between 3% (intended as
>2%) and 20%; G3 with 21 or more mitoses per 2 mm2 and
Ki-67 index >20%.
The G1 and G2 well-differentiated NETs usually display
diffuse and intense expression of the two general immuno-
histochemical neuroendocrine markers, chromogranin A
and synaptophysin [28]. Punctate necrosis is per se
indicative of a more aggressive tumor and points to a G2
or G3 status, which is then determined by the mitotic count
and the proliferation fraction. G3 indicates a poorly
differentiated neuroendocrine carcinoma with high mitotic
counts/Ki-67 index, fields of necrosis, significantly reduced
chromogranin A expression and intense staining for
synaptophysin, meeting the current WHO histological
criteria [5, 8, 34].
Mitotic count and Ki-67 index As for the foregut proposal,
mitoses should be counted on hematoxylin and eosin stained
slides in at least 40 HPFwhen possible. The mitoses should be
assessed in areas where they are most frequent after a general
slide survey. For Ki-67 assessment, the MIB1 antibody is
recommended at the conditions that have been established at
the laboratory in question. The Ki-67 index should be
assessed in 2,000 tumor cells in areas where the highest
nuclear labeling is observed (often but not exclusively at the
tumor periphery).
Concluding remarks
The TNM staging system proposed here for midgut and
hindgut NETs closely follows its forerunner for foregut
tumors [27]. It has the same basis, i.e., the current WHO
classifications of GEP-NETs, and results from a consensus
conference held by specialists and practicing physicians
involved in the management of patients with GEP-NETs.
The grading system described here is substantially identical
to that proposed for foregut NETs and again attempts to
close the gap between the advances of the most recent WHO
classifications and the need for a better prognostic assess-
ment of NETs. These proposals, as well as those already
published, await confirmation by clinicopathologic work.
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